The ABPI has formally appointed Sandra Auld to the role of ABPI Scotland Director.
Sandra will be responsible for helping to address the health needs of Scottish patients and representing the interests of the pharmaceutical industry in Scotland.
Sandra will spearhead the ABPI Scotland team, working closely with the Scottish Government and NHS Scotland. The Scotland team also represents ABPI members in a number of groups, including the Scottish Medicines Consortium (SMC), the Patient Access Scheme Assessment Group (PASAG) and the Scottish Government’s Life Sciences Advisory Board (LiSAB). It also provides the secretariat for the Scottish Parliament’s cross party group on life sciences.
Sandra has a diverse background with NHS, university and private sector experience and joined the ABPI as Operations Director in May 2010. Previously Sandra worked for the NHS Scottish Centre for Telehealth. Prior to this Sandra spent 10 years heading a nurse research team with the Department of Public Health Sciences at the University of Edinburgh. She later joined Solvay Healthcare, then Boehringer Ingelheim as Health Policy Manager.
Welcoming Sandra’s appointment, Alison Clough, the ABPI’s Acting CEO, said: “I am delighted to appoint Sandra as our Director of ABPI Scotland. Sandra’s range of knowledge and experience will be hugely beneficial in working closely with members, partners and stakeholders across the life sciences environment in Scotland and in helping to improve the access to and use of new and innovative medicines for Scottish patients. In addition, Sandra will continue to lead all initiatives to improve the environment for the pharmaceutical industry in Scotland and its role in contributing to the UK economy.”
Commenting on her appointment, Sandra said: “I am absolutely delighted to become the Director of ABPI Scotland. The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing value of new and innovative medicines.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com